Cargando…
The Long Term Residual Effects of COVID-Associated Coagulopathy
During the acute phase of COVID-19, many patients experience a complex coagulopathy characterized by a procoagulant pattern. The present study investigates the persistence of hemostatic changes in post-COVID patients at a long-term follow up, and the link with the persistence of physical and neurops...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049638/ https://www.ncbi.nlm.nih.gov/pubmed/36982589 http://dx.doi.org/10.3390/ijms24065514 |
_version_ | 1785014501395922944 |
---|---|
author | Ranucci, Marco Baryshnikova, Ekaterina Anguissola, Martina Pugliese, Sara Falco, Mara Menicanti, Lorenzo |
author_facet | Ranucci, Marco Baryshnikova, Ekaterina Anguissola, Martina Pugliese, Sara Falco, Mara Menicanti, Lorenzo |
author_sort | Ranucci, Marco |
collection | PubMed |
description | During the acute phase of COVID-19, many patients experience a complex coagulopathy characterized by a procoagulant pattern. The present study investigates the persistence of hemostatic changes in post-COVID patients at a long-term follow up, and the link with the persistence of physical and neuropsychological symptoms. We completed a prospective cohort study on 102 post-COVID patients. Standard coagulation and viscoelastic tests were performed, along with an assessment of persistent symptoms and recording of acute phase details. A procoagulant state was adjudicated in the presence of fibrinogen > 400 mg/dL, or D-dimer > 500 ng/mL, or platelet count > 450,000 cells/µL, or a maxim clot lysis at viscoelastic test < 2%. A procoagulant state was identified in 75% of the patients at 3 months follow up, 50% at 6 months, and 30% at 12–18 months. Factors associated with the persistence of a procoagulant state were age, severity of the acute phase, and persistence of symptoms. Patients with major physical symptoms carry a procoagulant state relative risk of 2.8 (95% confidence interval 1.17–6.7, p = 0.019). The association between persistent symptoms and a procoagulant state raises the hypothesis that an ongoing process of thrombi formation and/or persistent microthrombosis may be responsible for the main physical symptoms in long-COVID patients. |
format | Online Article Text |
id | pubmed-10049638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100496382023-03-29 The Long Term Residual Effects of COVID-Associated Coagulopathy Ranucci, Marco Baryshnikova, Ekaterina Anguissola, Martina Pugliese, Sara Falco, Mara Menicanti, Lorenzo Int J Mol Sci Article During the acute phase of COVID-19, many patients experience a complex coagulopathy characterized by a procoagulant pattern. The present study investigates the persistence of hemostatic changes in post-COVID patients at a long-term follow up, and the link with the persistence of physical and neuropsychological symptoms. We completed a prospective cohort study on 102 post-COVID patients. Standard coagulation and viscoelastic tests were performed, along with an assessment of persistent symptoms and recording of acute phase details. A procoagulant state was adjudicated in the presence of fibrinogen > 400 mg/dL, or D-dimer > 500 ng/mL, or platelet count > 450,000 cells/µL, or a maxim clot lysis at viscoelastic test < 2%. A procoagulant state was identified in 75% of the patients at 3 months follow up, 50% at 6 months, and 30% at 12–18 months. Factors associated with the persistence of a procoagulant state were age, severity of the acute phase, and persistence of symptoms. Patients with major physical symptoms carry a procoagulant state relative risk of 2.8 (95% confidence interval 1.17–6.7, p = 0.019). The association between persistent symptoms and a procoagulant state raises the hypothesis that an ongoing process of thrombi formation and/or persistent microthrombosis may be responsible for the main physical symptoms in long-COVID patients. MDPI 2023-03-14 /pmc/articles/PMC10049638/ /pubmed/36982589 http://dx.doi.org/10.3390/ijms24065514 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ranucci, Marco Baryshnikova, Ekaterina Anguissola, Martina Pugliese, Sara Falco, Mara Menicanti, Lorenzo The Long Term Residual Effects of COVID-Associated Coagulopathy |
title | The Long Term Residual Effects of COVID-Associated Coagulopathy |
title_full | The Long Term Residual Effects of COVID-Associated Coagulopathy |
title_fullStr | The Long Term Residual Effects of COVID-Associated Coagulopathy |
title_full_unstemmed | The Long Term Residual Effects of COVID-Associated Coagulopathy |
title_short | The Long Term Residual Effects of COVID-Associated Coagulopathy |
title_sort | long term residual effects of covid-associated coagulopathy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049638/ https://www.ncbi.nlm.nih.gov/pubmed/36982589 http://dx.doi.org/10.3390/ijms24065514 |
work_keys_str_mv | AT ranuccimarco thelongtermresidualeffectsofcovidassociatedcoagulopathy AT baryshnikovaekaterina thelongtermresidualeffectsofcovidassociatedcoagulopathy AT anguissolamartina thelongtermresidualeffectsofcovidassociatedcoagulopathy AT pugliesesara thelongtermresidualeffectsofcovidassociatedcoagulopathy AT falcomara thelongtermresidualeffectsofcovidassociatedcoagulopathy AT menicantilorenzo thelongtermresidualeffectsofcovidassociatedcoagulopathy AT ranuccimarco longtermresidualeffectsofcovidassociatedcoagulopathy AT baryshnikovaekaterina longtermresidualeffectsofcovidassociatedcoagulopathy AT anguissolamartina longtermresidualeffectsofcovidassociatedcoagulopathy AT pugliesesara longtermresidualeffectsofcovidassociatedcoagulopathy AT falcomara longtermresidualeffectsofcovidassociatedcoagulopathy AT menicantilorenzo longtermresidualeffectsofcovidassociatedcoagulopathy |